2,2'-bithiazolidine | 77771-20-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 2,2'-bithiazolidine
• 英文别名: 2.2'-Di-thiazolidin；octahydro-[2,2']bithiazolyl；2-(1,3-thiazolidin-2-yl)-1,3-thiazolidine
• CAS: 77771-20-1
• 化学式: C₆H₁₂N₂S₂
• 分子量: 176.307
• InChiKey: BALPQDWQADEPOU-UHFFFAOYSA-N

物化性质

• 熔点：
  165-167 °C
• 沸点：
  355.4±37.0 °C(Predicted)
• 密度：
  1.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  74.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  草酸醛 、 巯基乙胺 在 1,4-二氧六环 作用下， 生成 2,2'-bithiazolidine
  参考文献：
  名称：

  Kuhn; Drawert, Justus Liebigs Annalen der Chemie, 1954, vol. 590, p. 55,61

  摘要：

  DOI：

文献信息

• HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
  申请人：EA PHARMA CO., LTD.

  公开号：US20160332999A1

  公开（公告）日：2016-11-17

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

  本发明提供了一种由公式(I)表示的化合物： 其中，每个符号如说明书中所定义，或者其药用可接受的盐。该化合物具有优越的TRPA1拮抗剂活性，并且可以提供一种用于预防或治疗涉及TRPA1拮抗剂和TRPA1的疾病的药物。
• CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME
  申请人：EA PHARMA CO., LTD.

  公开号：EP3330266A1

  公开（公告）日：2018-06-06

  A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has superior TRPA1 antagonist activity, and the compound or a pharmaceutically acceptable salt thereof is useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

  化合物的化学式为(I)： 其中每个符号的定义如描述中所定义， 或其药学上可接受的盐具有优越的TRPA1拮抗活性，该化合物或其药学上可接受的盐对涉及TRPA1拮抗剂和TRPA1的疾病的预防或治疗是有用的。
• BICYCLIC HETEROCYCLIC COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1961745A1

  公开（公告）日：2008-08-27

  A compound represented by the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof: wherein X, Y, and W each independently represent a carbon atom or a nitrogen atom; Z represents CH or a nitrogen atom; R1 represents (1) C3-10 branched alkyl which may be substituted or (2) -(CH2)m-NR4R5; R2 and R3 each independently represent (1) a hydrogen atom, (2) C1-4 alkyl which may be substituted with a halogen atom, hydroxy which may be protected, amino which may be protected, or carboxyl which may be protected, (3) C2-4 alkenyl, (4) C2-4 alkynyl, (5) nitrile, (6) COOR6, (7) CONR7R8, (8) COR101, (9) S(O)nR102, or (10) a halogen atom, in which R6 represents a hydrogen atom or C1-4 alkyl, R7 and R8 each independently represent a hydrogen atom or C1-4 alkyl, R101 represents a hydrogen atom or C1-4 alkyl, R102 represents C1-4 alkyl, n represents 1 or 2; and Ar represents an aromatic ring which may be substituted, is useful as a pharmacologically active ingredient having a CRF antagonist action in preventing and/or treating neuropsychiatric diseases, diseases of peripheral organs or the like.

  公式（I）表示的化合物，其盐，其N-氧化物，其溶剂合物或其前药：其中X，Y和W分别独立表示碳原子或氮原子；Z表示CH或氮原子；R1表示（1）可能被取代的C3-10支链烷基或（2）-(CH2)m-NR4R5；R2和R3分别独立表示（1）氢原子，（2）可能被卤原子取代的C1-4烷基，可能被保护的羟基，可能被保护的氨基，或可能被保护的羧基，（3）C2-4烯基，（4）C2-4炔基，（5）腈基，（6）COOR6，（7）CONR7R8，（8）COR101，（9）S（O）nR102，或（10）卤原子，其中R6表示氢原子或C1-4烷基，R7和R8分别独立表示氢原子或C1-4烷基，R101表示氢原子或C1-4烷基，R102表示C1-4烷基，n表示1或2；Ar表示可能被取代的芳香环，用作在预防和/或治疗神经精神疾病，外周器官疾病等方面具有CRF拮抗作用的药理活性成分。
• Nitrogenous heterocyclic compounds and medical use thereof
  申请人：Takahashi Kanji

  公开号：US20070010529A1

  公开（公告）日：2007-01-11

  The present invention relates to a compound represented by formula (I): (wherein all the symbols have the same meanings as defined in the above description) and a production method and use thereof. The compounds represented by formula (I), or its salt, N-oxide or solvate, or a prodrug thereof have p38 MAP kinase inhibitory activity, and are useful in the prevention and/or treatment of those diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokine or chemokine, or by over response thereto, namely cytokine-mediated diseases such as inflammatory diseases, respiratory diseases, cardiovascular disease, central nervous system diseases, and the like.

  本发明涉及一种由以下式表示的化合物：(其中所有符号的含义与上述描述中定义的相同)，以及其生产方法和用途。由式(I)表示的化合物，或其盐、N-氧化物或溶剂合物，或其前药，在p38 MAP激酶抑制活性方面具有作用，并且在预防和/或治疗那些据称由细胞因子异常产生或恶化引起，或由过度反应引起的疾病方面有用，即细胞因子介导的疾病，如炎症性疾病、呼吸系统疾病、心血管疾病、中枢神经系统疾病等。
• BENZENE DERIVATIVE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20210332009A1

  公开（公告）日：2021-10-28

  A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).

  通式（I）表示的化合物（在公式中，所有符号如描述中所述）或其盐具有强大的神经保护和/或修复活性，因此可用作神经病变的治疗剂（例如，慢性炎症性脱髓鞘性多发性神经病、吉兰-巴雷综合征、周围动脉炎、过敏性血管炎、糖尿病周围神经病变、神经卡压病变、与化疗药物治疗相关的周围神经病变，或与沙科-玛丽-图斯病相关的周围神经病变）。